{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:36:01Z","timestamp":1776087361906,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":116,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"ESMO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Fellowship at Institut Jules Bordet"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1093\/annonc\/mdz280","type":"journal-article","created":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T11:18:32Z","timestamp":1565522312000},"page":"x27-x42","source":"Crossref","is-referenced-by-count":75,"special_numbering":"S10","title":["Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-3544","authenticated-orcid":false,"given":"M.","family":"Brand\u00e3o","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5573-0711","authenticated-orcid":false,"given":"R.","family":"Caparica","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9879-6048","authenticated-orcid":false,"given":"D.","family":"Eiger","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"E.","family":"de Azambuja","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"6","key":"10.1093\/annonc\/mdz280_bb0010","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1093\/annonc\/mdz280_bb0015","doi-asserted-by":"crossref","first-page":"273.","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"10.1093\/annonc\/mdz280_bb0020","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1158\/1078-0432.CCR-13-0884","article-title":"PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system","volume":"19","author":"Beaver","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1093\/annonc\/mdz280_bb0025","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1158\/1078-0432.CCR-09-2828","article-title":"Predictive biomarkers of sensitivity to the phosphatidylinositol 3\u2032 kinase inhibitor GDC-0941 in breast cancer preclinical models","volume":"16","author":"O\u2019Brien","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1093\/annonc\/mdz280_bb0030","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2015.63.9179","article-title":"Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer","volume":"34","author":"Schmid","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdz280_bb0035","doi-asserted-by":"crossref","first-page":"P2-08-02","DOI":"10.1158\/1538-7445.SABCS18-P2-08-02","article-title":"Abstract P2-08-02: interaction of PIK3CA mutation subclasses with response to preoperative treatment with the PI3K inhibitor pictilisib in patients with estrogen receptor-positive breast cancer","volume":"79","author":"Schmid","year":"2019","journal-title":"Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdz280_bb0040","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","article-title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Baselga","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz280_bb0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","article-title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Di Leo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz280_bb0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdw562","article-title":"A randomized adaptive phase II\/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)","volume":"28","author":"Mart\u00edn","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz280_bb0055","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(16)00106-6","article-title":"Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Krop","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdz280_bb0060","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/annonc\/mdw320","volume":"27","author":"Vuylsteke","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz280_bb0065","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx440.001","article-title":"LBA10_PRPrimary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+\/HER2-negative early breast cancer (EBC)","author":"Saura","year":"2017","journal-title":"Ann Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz280_bb0070","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2019.37.15_suppl.1050","article-title":"Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive\/HER2-negative early-stage breast cancer from the LORELEI trial","volume":"37","author":"Nuciforo","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Suppl 9","key":"10.1093\/annonc\/mdz280_bb0075","doi-asserted-by":"crossref","first-page":"PD5-2","DOI":"10.1158\/1538-7445.SABCS14-PD5-2","article-title":"Abstract PD5-2: ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer","volume":"75","author":"Saura","year":"2015","journal-title":"Cancer Res"},{"issue":"18","key":"10.1093\/annonc\/mdz280_bb0080","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1158\/1078-0432.CCR-18-0613","article-title":"Phase II study of taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor-positive advanced breast cancer","volume":"24","author":"Dickler","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz280_bb0085","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2019.37.15_suppl.1051","volume":"37","author":"Pascual","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Suppl 18","key":"10.1093\/annonc\/mdz280_bb0090","doi-asserted-by":"crossref","first-page":"LBA1006","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA1006","article-title":"Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary analysis from SANDPIPER","volume":"36","author":"Baselga","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdz280_bb0095","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1158\/1078-0432.CCR-18-3160","article-title":"A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NEO-ORB)","volume":"25","author":"Mayer","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdz280_bb0100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","article-title":"A phase Ib study of alpelisib (BYL719), a PI3K\u03b1-specific inhibitor, with letrozole in ER+\/HER2- metastatic breast cancer","volume":"23","author":"Mayer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdz280_bb0105","first-page":"e184475.","article-title":"Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial","author":"Juric","year":"2018","journal-title":"JAMA Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz280_bb0110","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1200\/JCO.2018.36.15_suppl.1018","article-title":"Clinical and biomarker results from phase I\/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer","volume":"36","author":"Sharma","year":"2018","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1093\/annonc\/mdz280_bb0115","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdz280_bb0120","doi-asserted-by":"crossref","first-page":"GS3-08","DOI":"10.1158\/1538-7445.SABCS18-GS3-08","article-title":"Abstract GS3-08: alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial","volume":"79","author":"Juric","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdz280_bb0125","doi-asserted-by":"crossref","first-page":"201.","DOI":"10.1186\/bcr3605","article-title":"PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data","volume":"16","author":"Zardavas","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"22","key":"10.1093\/annonc\/mdz280_bb0130","doi-asserted-by":"crossref","first-page":"10208","DOI":"10.1073\/pnas.0907011107","article-title":"PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer","volume":"107","author":"Loi","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1093\/annonc\/mdz280_bb0135","doi-asserted-by":"crossref","first-page":"e53292","DOI":"10.1371\/journal.pone.0053292","article-title":"PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer","volume":"8","author":"Loi","year":"2013","journal-title":"PLoS One"},{"issue":"7605","key":"10.1093\/annonc\/mdz280_bb0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature18003","article-title":"Proteogenomics connects somatic mutations to signalling in breast cancer","volume":"534","author":"Mertins","year":"2016","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdz280_bb0145","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz095","article-title":"1ODouble PIK3CA mutations in cis enhance PI3K\u03b1 oncogene activation and sensitivity to PI3K\u03b1 inhibitors in breast cancer","author":"Vasan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz280_bb0150","series-title":"Resistance to Anti-cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways","first-page":"117","article-title":"Mechanisms of Resistance to PI3K and AKT Inhibitors","author":"Castel","year":"2018"},{"issue":"283","key":"10.1093\/annonc\/mdz280_bb0155","doi-asserted-by":"crossref","first-page":"283ra51.","DOI":"10.1126\/scitranslmed.aaa4442","article-title":"PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer","volume":"7","author":"Bosch","year":"2015","journal-title":"Sci Transl Med"},{"issue":"6331","key":"10.1093\/annonc\/mdz280_bb0160","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1126\/science.aah6893","article-title":"PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D","volume":"355","author":"Toska","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1093\/annonc\/mdz280_bb0165","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","article-title":"CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors","volume":"26","author":"Vora","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdz280_bb0170","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz100.003","article-title":"152OFirst report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)","author":"Aftimos","year":"2019","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1093\/annonc\/mdz280_bb0175","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1200\/JCO.2014.55.9591","article-title":"PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor-positive breast cancer?","volume":"32","author":"Mayer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdz280_bb0180","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2013.54.0518","article-title":"Stand up to cancer phase Ib study of Pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"32","author":"Mayer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7538","key":"10.1093\/annonc\/mdz280_bb0185","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature13948","article-title":"Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor","volume":"518","author":"Juric","year":"2015","journal-title":"Nature"},{"issue":"35","key":"10.1093\/annonc\/mdz280_bb0190","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1073\/pnas.0802655105","article-title":"PTEN-deficient cancers depend on PIK3CB","volume":"105","author":"Wee","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"10.1093\/annonc\/mdz280_bb0195","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2015.63.9161","article-title":"Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2\u2014overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3","volume":"34","author":"Andr\u00e9","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7719","key":"10.1093\/annonc\/mdz280_bb0200","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","article-title":"Suppression of insulin feedback enhances the efficacy of PI3K inhibitors","volume":"560","author":"Hopkins","year":"2018","journal-title":"Nature"},{"issue":"22","key":"10.1093\/annonc\/mdz280_bb0205","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1158\/1078-0432.CCR-17-1260","article-title":"A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and HER2-negative breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdz280_bb0210","unstructured":"FDA approves first PI3K inhibitor for breast cancer. http:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-pi3k-inhibitor-breast-cancer (7 August 2019, date last accessed)."},{"issue":"3","key":"10.1093\/annonc\/mdz280_bb0215","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/annonc\/mdz036","article-title":"Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"30","author":"Condorelli","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz280_bb0220","doi-asserted-by":"crossref","first-page":"896.","DOI":"10.1038\/s41467-018-03215-x","article-title":"Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer","volume":"9","author":"O\u2019Leary","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"10.1093\/annonc\/mdz280_bb0225","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrclinonc.2015.123","article-title":"Precision medicine for metastatic breast cancer\u2014limitations and solutions","volume":"12","author":"Arnedos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz280_bb0230","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/bjc.2017.25","article-title":"Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2\u2212 advanced breast cancer: results from BOLERO-2","volume":"116","author":"Moynahan","year":"2017","journal-title":"Br J Cancer"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdz280_bb0235","doi-asserted-by":"crossref","first-page":"OT3-06-01","DOI":"10.1158\/1538-7445.SABCS18-OT3-06-01","article-title":"Abstract OT3-06-01: phase Ib clinical trial of coPANlisib in combination with Trastuzumab emtansine (T-DM1) in pre-treated unresectable locally advanced or metastatic HER2-positive breAst cancer (BC) \u201cPANTHERA\u201d-CTRIAL-IE 17-13","volume":"79","author":"Hassan","year":"2019","journal-title":"Cancer Res"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdz280_bb0240","doi-asserted-by":"crossref","first-page":"P3-14-01","DOI":"10.1158\/1538-7445.SABCS15-P3-14-01","article-title":"Abstract P3-14-01: phase Ib\/II study of ribociclib and alpelisib and letrozole in ER+, HER2\u2013 breast cancer: safety, preliminary efficacy and molecular analysis","volume":"76","author":"Juric","year":"2016","journal-title":"Cancer Res"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz280_bb0245","doi-asserted-by":"crossref","first-page":"TPS1113","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS1113","article-title":"Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced\/recurrent breast cancer (B2151009; NCT02684032)","volume":"35","author":"Forero-Torres","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz280_bb0250","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clbc.2017.10.014","article-title":"A phase I trial of the PI3K inhibitor buparlisib combined with capecitabine in patients with metastatic breast cancer","volume":"18","author":"McRee","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz280_bb0255","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1200\/jco.2014.32.15_suppl.627","article-title":"Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC)","volume":"32","author":"Cruz Zambrano","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz280_bb0260","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1200\/jco.2014.32.15_suppl.621","article-title":"Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC)","volume":"32","author":"Rodon Ahnert","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz280_bb0265","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-017-4596-7","article-title":"Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy","volume":"168","author":"Pistilli","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1093\/annonc\/mdz280_bb0270","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/1078-0432.CCR-13-1070","article-title":"Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy","volume":"20","author":"Saura","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdz280_bb0275","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-014-3248-4","article-title":"Phase I\/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer","volume":"149","author":"Tolaney","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz280_bb0280","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1200\/jco.2015.33.15_suppl.590","article-title":"Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)","volume":"33","author":"Shah","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz280_bb0285","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2017.08.025","article-title":"PIKHER2: a phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer","volume":"86","author":"Guerin","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz280_bb0290","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1200\/JCO.2017.35.15_suppl.1026","article-title":"Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy","volume":"35","author":"Jain","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz280_bb0295","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2017.35.15_suppl.1030","article-title":"A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC)","volume":"35","author":"Metzger Filho","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz280_bb0300","doi-asserted-by":"crossref","first-page":"109.","DOI":"10.1186\/s13058-018-1015-x","article-title":"A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer","volume":"20","author":"Sch\u00f6ffski","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"Suppl 14","key":"10.1093\/annonc\/mdz280_bb0305","doi-asserted-by":"crossref","first-page":"CT061","DOI":"10.1158\/1538-7445.AM2016-CT061","article-title":"Abstract CT061: a phase Ib study of alpelisib (BYL719) + everolimus \u00b1 exemestane in patients with advanced solid tumors or HR+\/HER2-breast cancer","volume":"76","author":"Baselga","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdz280_bb0310","doi-asserted-by":"crossref","first-page":"R9.","DOI":"10.1186\/bcr3601","article-title":"Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells","volume":"16","author":"Rexer","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"29","key":"10.1093\/annonc\/mdz280_bb0315","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2014.55.7876","article-title":"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer","volume":"32","author":"Loibl","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz280_bb0320","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2017.08.020","article-title":"Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: a randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)","volume":"85","author":"Loibl","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdz280_bb0325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bjc.6601048","article-title":"Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells","volume":"89","author":"Jin","year":"2003","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1093\/annonc\/mdz280_bb0330","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer","volume":"33","author":"Majewski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdz280_bb0335","doi-asserted-by":"crossref","first-page":"631.","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"10.1093\/annonc\/mdz280_bb0340","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1158\/1078-0432.CCR-06-1535","article-title":"Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches","volume":"12","author":"Moy","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdz280_bb0345","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/ijms14010108","article-title":"Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance","volume":"14","author":"Garc\u00eda-Becerra","year":"2012","journal-title":"IJMS"},{"issue":"4","key":"10.1093\/annonc\/mdz280_bb0350","doi-asserted-by":"crossref","first-page":"406.","DOI":"10.1186\/s13058-014-0406-x","article-title":"PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors","volume":"16","author":"Lehmann","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdz280_bb0355","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1158\/1078-0432.CCR-08-1763","article-title":"Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer","volume":"15","author":"Gonzalez-Angulo","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdz280_bb0360","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1535-7163.MCT-13-0655","article-title":"Activation of AR sensitizes breast carcinomas to NVP-BEZ235\u2019s therapeutic effect mediated by PTEN and KLLN upregulation","volume":"13","author":"Wang","year":"2014","journal-title":"Mol Cancer Ther"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420343726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420343726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/Supplement_10\/x27\/31574988\/mdz280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/Supplement_10\/x27\/31574988\/mdz280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T12:42:44Z","timestamp":1664109764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420343726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":71,"alternative-id":["S0923753420343726"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz280","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}